Brief: IRLAB Strengthens Patent Protection For Phase IIb/III Drug Candidate Mesdopetam
08/12/2020 07:57
Dec 8 (Reuters) - IRLAB Therapeutics AB IRLABa.ST :
* IRLAB STRENGTHENS PATENT PROTECTION FOR PHASE IIB/III DRUG
CANDIDATE MESDOPETAM
* ANNOUNCED THAT WORLD INTELLECTUAL PROPERTY ORGANIZATION
HAS
PUBLISHED A NEW PATENT APPLICATION CONCERNING DRUG CANDIDATE
MESDOPETAM (IRL790)
* COMPOSITION OF MATTER PATENT MAY EXTEND MARKET EXCLUSIVITY
OF
MESDOPETAM BY UP TO EIGHT YEARS COMPARED WITH CURRENT PATENT
PROTECTION
Source text for Eikon: ID:nWkrbrlm56
Further company coverage: IRLABa.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587696600;))